Abstract: A topical nail treat may include a topical nail solution including flucytosine, clotrimazole, diclofenac and DMSO. The topical nails solution may be applied to nail surfaces to treat or prevent a nail infection. A gel or ointment may be applied to nails over the topical nail solution.

Abstract: A method of making a pharmaceutical composition for delivery to the lower respiratory tract via nebulization within a sterile diluent includes mixing dry powder ingredients including a beta agonist or anticholinergic and one or more additional ingredients to formulate a dry powder mixture for mixing with the sterile diluent.

Abstract: A compounded capsule may include cannabidiol powder for combining with a solution, cream, gel, suspension or ointment for administration to a skin surface. The compounded capsule may also include xylitol powder.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more antimicrobial agents such as mupirocin.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.

Abstract: A method of compounding a topical cream includes combining ingredients including lidocaine and prilocaine, 2.5%/2.5%, cream, lidocaine hydrochloride, 4%, topical solution; and mixing the ingredients to generate a cream.

Abstract: A topical nail treat may include a topical nail solution including flucytosine, clotrimazole, diclofenac and DMSO. The topical nails solution may be applied to nail surfaces to treat or prevent a nail infection. A gel or ointment may be applied to nails over the topical nail solution.

Abstract: A method of powderizing a dry cake pharmaceutical drug product for injection within a vial may include securing a vial containing a dry cake pharmaceutical drug product for injection to a shaker device and powderizing the dry cake pharmaceutical drug product within the vial by shaking the vial with the shaker device operated at between about 100 to about 5000 cycles per minute for between about 10 minutes and about 1 hour.

Abstract: A method of managing non-infective nasal symptoms may include combining a steroid with a diluent, and acetylcysteine, azelastine, or theophylline. The combined ingredients may be mixed to formulate a topical composition for intranasal irrigation or nebulization. The steroid may include fluticasone, budesonide, or methylprednisolone.

Abstract: A method of compounding a topical cream includes combining ingredients including lidocaine hydrochloride, 4%, topical solution, diclofenac sodium, 1.5%, topical solution, lidocaine hydrochloride USP powder, and diclofenac sodium powder.

Abstract: A method of treating a hyperkeratotic skin condition includes combining contents of a compounded capsule with corticosteroid cream or ointment that includes a high potency corticosteroid to formulate a topical composition for application to a skin area affected by hyperkeratosis. The contents of the capsule may include urea powder, and the corticosteroid cream or ointment may include Clobetasol Propionate Cream or Ointment, Diflorasone Diacetate Cream or Ointment, Amcinonide Cream or Ointment, Betamethasone Dipropionate Cream or Ointment, Desoximetasone Cream or Ointment, Fluocinonide Cream or Ointment, Halcinonide Cream or Ointment, Halobetasol Propionate Cream or Ointment, Mometasone Furoate Cream or Ointment, Flurandrenolide Cream or Ointment, or a combination thereof.

Abstract: A method of treating a fungal infection may include formulating a topical treatment solution comprising combining itraconazole oral solution, 10 mg/mL, and a diluent. The itraconazole oral solution, 10 mg/mL, may include propylene glycol and at least one of cherry flavor or caramel flavor. The method may also include topically administering the topical treatment solution to the subject by contacting an infected skin surface of the subject with the topical treatment solution.

Abstract: A method of making a pharmaceutical composition for delivery to the lower respiratory tract via nebulization within a sterile diluent includes mixing dry powder ingredients including a beta agonist or anticholinergic and one or more additional ingredients to formulate a dry powder mixture for mixing with the sterile diluent.

Abstract: A method of treating a bacterial infection of a subject includes topically administering a topical composition that includes nitrofurantoin combined with a carrier. The topical composition may be administered by contacting a tissue surface of the subject to be treated with the topical composition such as skin or mucosal tissue.

Abstract: A method of powderizing a dry cake pharmaceutical drug product for injection within a vial may include securing a vial containing a dry cake pharmaceutical drug product for injection to a shaker device and powderizing the dry cake pharmaceutical drug product within the vial by shaking the vial with the shaker device operated at between about 100 to about 5000 cycles per minute for between about 10 minutes and about 1 hour.

Abstract: A method of treating a bacterial infection of a subject includes topically administering a topical composition that includes nitrofurantoin combined with a carrier. The topical composition may be administered by contacting a tissue surface of the subject to be treated with the topical composition such as skin or mucosal tissue.

Abstract: A compounded composition may include one or more active agents including betamethasone and one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The composition may be formulated by mixing dry powder including the active agents with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.

Abstract: A topical composition may include flucytosine, corn starch, lactose, talc, PEG-8, PEG-75, water, Spiraea ulmaria flower extract, zinc acetate, and propylene glycol.

Abstract: A method of treating bacterial or fungal nail infections may include mixing an antibiotic or antifungal injectable medication and a diluent to formulate a topical nail composition. The topical nail composition may be administered directly to a nail affected by the bacterial or fungal infection.

Abstract: A method of making a pharmaceutical composition for delivery to the lower respiratory tract via nebulization within a sterile diluent includes mixing dry powder ingredients including a beta agonist or anticholinergic and one or more additional ingredients to formulate a dry powder mixture for mixing with the sterile diluent.